文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

肺氧化还原失衡驱动中/重度COVID-19 ARDS早期纤维增殖反应并影响长期肺部异常

Pulmonary redox imbalance drives early fibroproliferative response in moderate/severe coronavirus disease-19 acute respiratory distress syndrome and impacts long-term lung abnormalities.
PubMed 文献 · Ann Intensive Care · 2024-05-12
一句话结论COVID-19中/重度ARDS患者早期BALF氧化还原失衡(GSSG、MDA升高,SOD、GSH降低)与纤维增殖标志物升高相关,并关联死亡及出院3个月肺部异常。

研究比较SARS-CoV-2 RNA阳性中/重度ARDS患者(n=65)与SARS-CoV-2 RNA阴性需机械通气的非ARDS患者(n=63)的基线BALF氧化还原与纤维增殖标志物。COVID-19 ARDS组入组时胸部CT纤维化评分及BALF NT-PCP-III、TGF-β1、GSSG、MDA均显著升高(均p<0.001),SOD、GSH显著降低(均p<0.001);NT-PCP-III和TGF-β1与GSSG、MDA正相关,与SOD、GSH负相关(均p<0.001)。ARDS组内死亡者(n=28)较存活者(n=37)纤维增殖更显著、氧化还原失衡更重(均p<0.001)。37例存活者出院3个月残余肺纤维化及肺功能损害较出院时改善(p<0.001),且与早期肺纤维增殖及氧化还原失衡相关(p<0.01)。

要点

  • 中/重度COVID-19 ARDS患者入组时BALF GSSG、MDA升高,SOD、GSH降低(均p<0.001),提示肺氧化还原失衡。
  • 同组BALF NT-PCP-III、TGF-β1升高(均p<0.001),且与GSSG、MDA正相关、与SOD、GSH负相关(均p<0.001)。
  • COVID-19 ARDS组内死亡者(n=28)较存活者(n=37)肺纤维增殖更显著、氧化还原失衡更重(均p<0.001)。
  • 37例存活者出院3个月残余肺纤维化及肺功能损害较出院时改善(p<0.001),与早期纤维增殖及氧化还原失衡相关(p<0.01)。
  • 研究结论认为COVID-19 ARDS早期肺氧化还原失衡驱动纤维增殖反应并增加死亡风险,长期肺部异常与早期纤维增殖及氧化还原失衡相关。

适用人群与场景

  • SARS-CoV-2 RNA阳性、中/重度ARDS患者(n=65,COVID-19 ARDS组)。
  • SARS-CoV-2 RNA阴性、需机械通气的非ARDS患者(n=63,非ARDS对照组)。
  • COVID-19 ARDS存活者随访亚组(n=37)。

研究设计与关键结果

  • 研究类型为病例对照与随访分析:比较SARS-CoV-2 RNA阳性中/重度ARDS患者(n=65)与SARS-CoV-2 RNA阴性需机械通气的非ARDS患者(n=63)的基线BALF指标。
  • 与非ARDS组相比,COVID-19 ARDS组入组时胸部CT纤维化评分升高(p<0.001),BALF NT-PCP-III(p<0.001)、TGF-β1(p<0.001)、GSSG(p<0.001)、MDA(p<0.001)浓度升高,SOD(p<0.001)和GSH(p<0.001)水平降低。
  • COVID-19 ARDS组BALF中NT-PCP-III和TGF-β1均与GSSG(p<0.001)、MDA(p<0.001)直接相关,与SOD(p<0.001)、GSH(p<0.001)负相关。
  • COVID-19 ARDS组内死亡者(n=28)较存活者(n=37)肺纤维增殖更显著(p<0.001)、氧化还原失衡更重(p<0.001)。
  • COVID-19 ARDS存活者随访(n=37)显示,出院3个月时影像学残余肺纤维化及肺功能损害较出院时改善(p<0.001),且与早期肺纤维增殖及氧化还原失衡相关(p<0.01)。

证据类型、等级与局限

  • 证据类型:病例对照研究及随访分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,COVID-19 ARDS患者早期发生的肺氧化还原失衡驱动纤维增殖反应并增加死亡风险,出院后长期肺部异常与早期肺纤维增殖及氧化还原失衡相关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: COVID-19-associated pulmonary fibrosis remains frequent. This study aimed to investigate pulmonary redox balance in COVID-19 ARDS patients and possible relationship with pulmonary fibrosis and long-term lung abnormalities.

METHODS: Baseline data, chest CT fibrosis scores, N-terminal peptide of alveolar collagen III (NT-PCP-III), transforming growth factor (TGF)-β1, superoxide dismutase (SOD), reduced glutathione (GSH), oxidized glutathione (GSSG) and malondialdehyde (MDA) in bronchoalveolar lavage fluid (BALF) were first collected and compared between SARS-CoV-2 RNA positive patients with moderate to severe ARDS (n = 65, COVID-19 ARDS) and SARS-CoV-2 RNA negative non-ARDS patients requiring mechanical ventilation (n = 63, non-ARDS). Then, correlations between fibroproliferative (NT-PCP-III and TGF-β1) and redox markers were analyzed within COVID-19 ARDS group, and comparisons between survivor and non-survivor subgroups were performed. Finally, follow-up of COVID-19 ARDS survivors was performed to analyze the relationship between pulmonary abnormalities, fibroproliferative and redox markers 3 months after discharge.

RESULTS: Compared with non-ARDS group, COVID-19 ARDS group had significantly elevated chest CT fibrosis scores (p < 0.001) and NT-PCP-III (p < 0.001), TGF-β1 (p < 0.001), GSSG (p < 0.001), and MDA (p < 0.001) concentrations on admission, while decreased SOD (p < 0.001) and GSH (p < 0.001) levels were observed in BALF. Both NT-PCP-III and TGF-β1 in BALF from COVID-19 ARDS group were directly correlated with GSSG (p < 0.001) and MDA (p < 0.001) and were inversely correlated with SOD (p < 0.001) and GSH (p < 0.001). Within COVID-19 ARDS group, non-survivors (n = 28) showed significant pulmonary fibroproliferation (p < 0.001) with more severe redox imbalance (p < 0.001) than survivors (n = 37). Furthermore, according to data from COVID-19 ARDS survivor follow-up (n = 37), radiographic residual pulmonary fibrosis and lung function impairment improved 3 months after discharge compared with discharge (p < 0.001) and were associated with early pulmonary fibroproliferation and redox imbalance (p < 0.01).

CONCLUSIONS: Pulmonary redox imbalance occurring early in COVID-19 ARDS patients drives fibroproliferative response and increases the risk of death. Long-term lung abnormalities post-COVID-19 are associated with early pulmonary fibroproliferation and redox imbalance.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Yang C, Tan Y, Li Z, et al. Pulmonary redox imbalance drives early fibroproliferative response in moderate/severe coronavirus disease-19 acute respiratory distress syndrome and impacts long-term lung abnormalities. Ann Intensive Care. 2024. PMID: 38735020. doi:10.1186/s13613-024-01293-3

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。